NCT04821141View on ClinicalTrials.gov

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Risk ReductionBreast Cancer
Interventions
DRUG

Bazedoxifene and Conjugated Estrogens

BZA (20 mg) plus CE (0.45 mg) taken together once daily

Trial Locations (5)

60601

RECRUITING

Northwestern Medical Center, Chicago

66160

RECRUITING

University of Kansas Medical Center, Kansas City

91010

RECRUITING

City of Hope Medical Center, Duarte

94115

RECRUITING

University of California San Francisco, San Francisco

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Kansas Medical Center

OTHER